• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Psychometric evaluation of the Dysphagia Symptom Questionnaire for adults and adolescents with eosinophilic esophagitis.嗜酸性食管炎成人及青少年吞咽困难症状问卷的心理测量评估
J Allergy Clin Immunol Glob. 2024 Jul 16;3(4):100302. doi: 10.1016/j.jacig.2024.100302. eCollection 2024 Nov.
2
Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension.布地奈德口服混悬液治疗的嗜酸性粒细胞性食管炎患者吞咽困难症状问卷的心理测量学验证
J Patient Rep Outcomes. 2017;1(1):3. doi: 10.1186/s41687-017-0006-5. Epub 2017 Sep 12.
3
Validation of the novel Eosinophilic Esophagitis Impact Questionnaire.新型嗜酸性粒细胞食管炎生活质量问卷的验证。
J Patient Rep Outcomes. 2023 Nov 27;7(1):120. doi: 10.1186/s41687-023-00654-z.
4
Qualitative assessment of the suitability of the Dysphagia Symptom Questionnaire to monitor dysphagia in children aged 7-10 years with eosinophilic esophagitis.对 Dysphagia Symptom Questionnaire 监测 7-10 岁嗜酸细胞性食管炎儿童吞咽困难的适用性进行定性评估。
J Patient Rep Outcomes. 2023 Oct 31;7(1):110. doi: 10.1186/s41687-023-00646-z.
5
Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis.开发并现场测试一种新型的针对嗜酸细胞性食管炎患者吞咽困难的患者报告结局测量量表。
Aliment Pharmacol Ther. 2013 Sep;38(6):634-42. doi: 10.1111/apt.12413. Epub 2013 Jul 9.
6
Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.度普利尤单抗治疗嗜酸性食管炎成人和青少年长达52周的疗效和安全性(LIBERTY EoE TREET研究):一项多中心、双盲、随机、安慰剂对照的3期试验
Lancet Gastroenterol Hepatol. 2023 Nov;8(11):990-1004. doi: 10.1016/S2468-1253(23)00204-2. Epub 2023 Aug 31.
7
Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.接受布地奈德混悬液治疗的嗜酸性食管炎患者吞咽困难和吞咽痛的改善。
Clin Gastroenterol Hepatol. 2021 Apr;19(4):699-706.e4. doi: 10.1016/j.cgh.2020.03.060. Epub 2020 Apr 6.
8
Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.布地奈德混悬液治疗嗜酸性粒细胞性食管炎:与安慰剂相比,可改善症状、内镜和组织学参数。
Gastroenterology. 2017 Mar;152(4):776-786.e5. doi: 10.1053/j.gastro.2016.11.021. Epub 2016 Nov 23.
9
Pooled Phase 2 and 3 Efficacy and Safety Data on Budesonide Oral Suspension in Adolescents with Eosinophilic Esophagitis.嗜酸粒细胞性食管炎青少年患者布地奈德混悬液的 2 期和 3 期疗效和安全性汇总数据。
J Pediatr Gastroenterol Nutr. 2023 Dec 1;77(6):760-768. doi: 10.1097/MPG.0000000000003948. Epub 2023 Sep 18.
10
Patient-Reported Dysphagia in Adults with Eosinophilic Esophagitis: Translation and Validation of the Swedish Eosinophilic Esophagitis Activity Index.成人嗜酸细胞性食管炎患者报告的吞咽困难:瑞典嗜酸细胞性食管炎活动指数的翻译和验证。
Dysphagia. 2022 Apr;37(2):286-296. doi: 10.1007/s00455-021-10277-5. Epub 2021 Mar 8.

引用本文的文献

1
Patient-Reported Outcome Measures in Benign Esophageal Disorders.良性食管疾病的患者报告结局指标
Am J Gastroenterol. 2025 Apr 7. doi: 10.14309/ajg.0000000000003467.

本文引用的文献

1
Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis.度普利尤单抗在成人和青少年嗜酸性食管炎中的应用。
N Engl J Med. 2022 Dec 22;387(25):2317-2330. doi: 10.1056/NEJMoa2205982.
2
EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe.嗜酸性食管炎的欧洲临床、环境和遗传决定因素登记处(EoE CONNECT):欧洲一项大规模流行病学研究的基本原理、设计和研究方案
Therap Adv Gastroenterol. 2022 Feb 2;15:17562848221074204. doi: 10.1177/17562848221074204. eCollection 2022.
3
Determination of a treatment response threshold for the Eosinophilic Esophagitis Endoscopic Reference Score.确定嗜酸性食管炎内镜参考评分的治疗反应阈值。
Endoscopy. 2022 Jul;54(7):635-643. doi: 10.1055/a-1675-7860. Epub 2022 Jan 11.
4
Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.布地奈德混悬液可改善嗜酸性食管炎患者的结局:来自 3 期试验的结果。
Clin Gastroenterol Hepatol. 2022 Mar;20(3):525-534.e10. doi: 10.1016/j.cgh.2021.04.022. Epub 2021 Apr 19.
5
Documenting the Journey of Patients with Eosinophilic Esophagitis and the Impact of the Disease on Patients and their Caregivers: A Cross-sectional, Qualitative Research Study.记录嗜酸性食管炎患者的病程以及该疾病对患者及其照顾者的影响:一项横断面定性研究。
Adv Ther. 2020 Oct;37(10):4458-4478. doi: 10.1007/s12325-020-01463-2. Epub 2020 Sep 3.
6
Epidemiology and risk factors for eosinophilic esophagitis: lessons for clinicians.嗜酸粒细胞性食管炎的流行病学和危险因素:对临床医生的启示。
Expert Rev Gastroenterol Hepatol. 2020 Nov;14(11):1069-1082. doi: 10.1080/17474124.2020.1806054. Epub 2020 Aug 24.
7
Symptom-based diagnostic approach for eosinophilic esophagitis.基于症状的嗜酸性粒细胞性食管炎诊断方法。
J Gastroenterol. 2020 Sep;55(9):833-845. doi: 10.1007/s00535-020-01701-y. Epub 2020 Jul 27.
8
Improvements in Dysphagia and Pain With Swallowing in Patients With Eosinophilic Esophagitis Receiving Budesonide Oral Suspension.接受布地奈德混悬液治疗的嗜酸性食管炎患者吞咽困难和吞咽痛的改善。
Clin Gastroenterol Hepatol. 2021 Apr;19(4):699-706.e4. doi: 10.1016/j.cgh.2020.03.060. Epub 2020 Apr 6.
9
Eosinophilic esophagitis: early diagnosis is the key.嗜酸性粒细胞性食管炎:早期诊断是关键。
Clin Exp Gastroenterol. 2019 Aug 15;12:391-399. doi: 10.2147/CEG.S175061. eCollection 2019.
10
Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial.布地奈德与氟替卡松治疗嗜酸细胞性食管炎的随机对照试验。
Gastroenterology. 2019 Jul;157(1):65-73.e5. doi: 10.1053/j.gastro.2019.03.014. Epub 2019 Mar 11.

嗜酸性食管炎成人及青少年吞咽困难症状问卷的心理测量评估

Psychometric evaluation of the Dysphagia Symptom Questionnaire for adults and adolescents with eosinophilic esophagitis.

作者信息

McCann Eilish, Peterson Kathryn A, Whalley Diane, Qin Shanshan, Tilton Sarette T, Kamat Siddhesh, Sun Xian, Dellon Evan S

机构信息

Regeneron Pharmaceuticals, Inc, Sleepy Hollow, NY.

University of Utah Health, Salt Lake City, Utah.

出版信息

J Allergy Clin Immunol Glob. 2024 Jul 16;3(4):100302. doi: 10.1016/j.jacig.2024.100302. eCollection 2024 Nov.

DOI:10.1016/j.jacig.2024.100302
PMID:39228895
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11369371/
Abstract

BACKGROUND

Eosinophilic esophagitis (EoE) is a chronic, inflammatory disease of the esophagus leading to symptoms of esophageal dysfunction; dysphagia is the most common symptom experienced by adults and adolescents.

OBJECTIVE

We sought to perform a psychometric evaluation of the Dysphagia Symptom Questionnaire (DSQ), a patient-reported outcome measure for patients with EoE.

METHODS

Using baseline and week 24 data from the randomized, interventional, multinational phase 3 R668-EE-1774 trial (NCT03633617), the measurement properties of the DSQ-including reliability, construct and known-groups validity, responsiveness, and interpretation of change-were evaluated.

RESULTS

The analysis population comprised 239 patients with EoE (age [mean ± SD], 28.1 ± 13.14 years; 63.6% male; 90.4% White). Intraclass correlation coefficients of 0.92 and 0.97 exceeded the acceptable reliability threshold (≥0.70). Construct validity correlations with EoE symptom and impact measures were moderate at baseline (|| = 0.44-0.55) and week 24 (|| = 0.55-0.69), and the DSQ biweekly total score discriminated among groups defined by disease severity. Analyses exploring interpretation of change from baseline on the DSQ biweekly total score indicated thresholds for within-patient improvement ranging from 9 to 23 points; a within-patient improvement from baseline of 13 points or greater could be considered clinically meaningful.

CONCLUSIONS

This analysis confirmed that the DSQ has acceptable distributional properties, test-retest reliability, construct validity, and ability to detect change. Therefore, the DSQ is a valid and reliable measure to assess the patient-reported symptom of dysphagia among adult and adolescent patients with EoE in the context of a clinical trial setting.

摘要

背景

嗜酸性粒细胞性食管炎(EoE)是一种食管慢性炎症性疾病,可导致食管功能障碍症状;吞咽困难是成人和青少年最常见的症状。

目的

我们旨在对吞咽困难症状问卷(DSQ)进行心理测量学评估,这是一种针对EoE患者的患者报告结局指标。

方法

使用随机、干预性、多国3期R668-EE-1774试验(NCT03633617)的基线和第24周数据,评估DSQ的测量属性,包括信度、结构效度和已知组效度、反应性以及变化的解释。

结果

分析人群包括239例EoE患者(年龄[均值±标准差],28.1±13.14岁;63.6%为男性;90.4%为白人)。组内相关系数为0.92和0.97,超过了可接受的信度阈值(≥0.70)。在基线时(|| = 0.44 - 0.55)和第24周时(|| = 0.55 - 0.69),DSQ与EoE症状和影响指标的结构效度相关性为中等,并且DSQ双周总分在由疾病严重程度定义的组间存在差异。探索DSQ双周总分相对于基线变化解释的分析表明,患者内改善的阈值范围为9至23分;患者相对于基线改善13分或更多可被认为具有临床意义。

结论

该分析证实DSQ具有可接受的分布特性、重测信度、结构效度以及检测变化的能力。因此,在临床试验环境中,DSQ是评估成年和青少年EoE患者报告的吞咽困难症状的有效且可靠的指标。